Proposal of combination therapies to treat refractory chronic migraine
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Chronic migraine, affecting people for over 15 days per month of which 8 show migraine features, severely reduces patients’ quality of life with great rate of associated disability. Onabotulinumtoxin A has been used in the prevention of chronic migraine for the last two decades. A recent pooled analysis of real-world data highlighted the efficacy of its use in combination with the most novel monoclonal antibodies targeting the machinery of the calcitonin gene-related peptide (CGRP) in refractory migraine. Moreover, the CRD42023393250 systematic review and meta-analysis registered in the National Institute for Health Research International prospective register of systematic reviews PROSPERO following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement supported the safety of onabotulinumtoxin A, demonstrating that it induces fewer treatment-related adverse events (TRAEs) than oral topiramate one of the most commonly used preventative drugs. Therefore, the present data together with the lack of appropriately designed, prospective studies prompt the proposal of clinical trials to assess the efficacy and safety of the combination treatment of onabotulinumtoxinA with monoclonal antibodies or gepants directed towards the pathway of CGRP.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Pier Giuseppe Milanesi, Giorgio Sandrini, Giuseppe Nappi, The genetics of ideological configurations , Confinia Cephalalgica: Vol. 26 No. 1 (2016)
- Damiana Scuteri, Laura Rombolà, Luigi Antonio Morrone, Shinobu Sakurada, Tsukasa Sakurada, Paolo Tonin, Giorgio Sandrini, Giacinto Bagetta, Maria Tiziana Corasaniti, Unbiased research is needed for rational translation of essential oils in clinic , Confinia Cephalalgica: Vol. 32 No. 3 (2022)
- Paolo Mazzarello, Giorgio Sandrini, Mariano Martini, Editorial - December 2023 , Confinia Cephalalgica: Vol. 33 No. 3 (2023)
- Licia Grazzi, Giorgio Sandrini, Cesare Peccarisi, How cultivate internal resources to improve physical and brain health , Confinia Cephalalgica: Vol. 33 No. 1 (2023)